{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:14Z","timestamp":1793727734569,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40120-023-00541-1","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:04:12Z","timestamp":1696849452000},"page":"1883-1907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer\u2019s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion"],"prefix":"10.1007","volume":"12","author":[{"given":"Arthur","family":"Esquer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-5582","authenticated-orcid":false,"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"541_CR1","unstructured":"Dementia [Internet]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Accessed 1 Dec 2022."},{"key":"541_CR2","first-page":"149","volume":"70","author":"J Dumurgier","year":"2020","unstructured":"Dumurgier J, Sabia S. Epidemiology of Alzheimer\u2019s disease: latest trends. Rev Prat. 2020;70:149\u201351.","journal-title":"Rev Prat"},{"key":"541_CR3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/alz.12638","volume":"18","author":"Alzheimer\u2019s disease facts and figures","year":"2022","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2022;18:700\u201389.","journal-title":"Alzheimers Dement"},{"key":"541_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS\u2013ADRDA criteria. Lancet Neurol. 2007;6:734\u201346.","journal-title":"Lancet Neurol"},{"key":"541_CR5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314.","journal-title":"Neurology"},{"key":"541_CR6","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, et al. Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology"},{"key":"541_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.mayocp.2017.02.011","volume":"92","author":"RJ Caselli","year":"2017","unstructured":"Caselli RJ, et al. Alzheimer disease: scientific breakthroughs and translational challenges. Mayo Clin Proc. 2017;92:978\u201394.","journal-title":"Mayo Clin Proc"},{"key":"541_CR8","first-page":"340ra72","volume":"8","author":"DK Vijaya Kumar","year":"2016","unstructured":"Vijaya Kumar DK, et al. Amyloid-\u03b2 Peptide Protects Against Microbial Infection In Mouse and Worm Models of Alzheimer\u2019s Disease. Sci Transl Med. 2016;8:340ra72.","journal-title":"Sci Transl Med."},{"key":"541_CR9","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, et al. The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease. Mol Psychiatry. 2021;26:5481\u2013503.","journal-title":"Mol Psychiatry"},{"key":"541_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuron.2011.04.009","volume":"70","author":"M Morris","year":"2011","unstructured":"Morris M, et al. The many faces of tau. Neuron. 2011;70:410\u201326.","journal-title":"Neuron"},{"key":"541_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","volume":"16","author":"M Mil\u00e0-Alom\u00e0","year":"2020","unstructured":"Mil\u00e0-Alom\u00e0 M, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer\u2019s continuum. Alzheimers Dement J Alzheimers Assoc. 2020;16:1358\u201371.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"541_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:32.","journal-title":"Mol Neurodegener"},{"key":"541_CR13","doi-asserted-by":"publisher","unstructured":"Levine, Kristin S et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron 2023; 111(7):1086\u20131093.e2. https:\/\/doi.org\/10.1016\/j.neuron.2022.12.029.","DOI":"10.1016\/j.neuron.2022.12.029"},{"key":"541_CR14","doi-asserted-by":"publisher","first-page":"eaau3333","DOI":"10.1126\/sciadv.aau3333","volume":"5","author":"SS Dominy","year":"2019","unstructured":"Dominy SS, et al. Porphyromonas gingivalis in Alzheimer\u2019s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5:eaau3333.","journal-title":"Sci Adv"},{"key":"541_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","volume":"41","author":"C-C Tan","year":"2014","unstructured":"Tan C-C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41:615\u201331.","journal-title":"J Alzheimers Dis"},{"key":"541_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1017\/S1041610215001830","volume":"28","author":"H Amieva","year":"2016","unstructured":"Amieva H, et al. Group and individual cognitive therapies in Alzheimer\u2019s disease: the ETNA3 randomized trial. Int Psychogeriatr. 2016;28:707\u201317.","journal-title":"Int Psychogeriatr"},{"key":"541_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0447.2006.00789.x","volume":"114","author":"DI Sitzer","year":"2006","unstructured":"Sitzer DI, et al. Cognitive training in Alzheimer\u2019s disease: a meta-analysis of the literature. Acta Psychiatr Scand. 2006;114:75\u201390.","journal-title":"Acta Psychiatr Scand"},{"key":"541_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105010","volume":"144","author":"SS Plotkin","year":"2020","unstructured":"Plotkin SS, Cashman NR. Passive immunotherapies targeting A\u03b2 and tau in Alzheimer\u2019s disease. Neurobiol Dis. 2020;144: 105010.","journal-title":"Neurobiol Dis"},{"key":"541_CR19","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/jnnp-2020-323497","volume":"91","author":"L Lu","year":"2020","unstructured":"Lu L, et al. Anti-A\u03b2 agents for mild to moderate Alzheimer\u2019s disease: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91:1316\u201324.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"541_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings J, et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement N Y N. 2022;8: e12295.","journal-title":"Alzheimers Dement N Y N"},{"key":"541_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00401-015-1489-x","volume":"130","author":"Y Bouter","year":"2015","unstructured":"Bouter Y, et al. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathol (Berl). 2015;130:713\u201329.","journal-title":"Acta Neuropathol (Berl)"},{"key":"541_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"541_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"541_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway S, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med. 2021;27:1187\u201396.","journal-title":"Nat Med"},{"key":"541_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/acn3.761","volume":"6","author":"C Leurent","year":"2019","unstructured":"Leurent C, et al. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy. Ann Clin Transl Neurol. 2019;6:795\u2013806.","journal-title":"Ann Clin Transl Neurol"},{"key":"541_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmb.2011.11.047","volume":"421","author":"SL La Porte","year":"2012","unstructured":"La Porte SL, et al. Structural basis of C-terminal \u03b2-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer\u2019s disease. J Mol Biol. 2012;421:525\u201336.","journal-title":"J Mol Biol"},{"key":"541_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trci.2017.04.003","volume":"3","author":"JW Landen","year":"2017","unstructured":"Landen JW, et al. Multiple-dose ponezumab for mild-to-moderate Alzheimer\u2019s disease: Safety and efficacy. Alzheimers Dement Transl Res Clin Interv. 2017;3:339\u201347.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"541_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79:1113.","journal-title":"JAMA Neurol"},{"issue":"1","key":"541_CR29","first-page":"195","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L et al. Lecanemab, aducanumab, and gantenerumab-binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurother J Am Soc Exp Neurother. 2023;20(1):195\u2013206.","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"541_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"The SCarlet RoAD Investigators","year":"2017","unstructured":"The SCarlet RoAD Investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:95.","journal-title":"Alzheimers Res Ther"},{"key":"541_CR31","unstructured":"Trontinemab | ALZFORUM [Internet]. https:\/\/www.alzforum.org\/therapeutics\/trontinemab. Accessed 9 Mar 2023."},{"key":"541_CR32","unstructured":"Hoffmann-La Roche. A Phase Ib\/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer\u2019s Disease [Internet]. clinicaltrials.gov; 2023 Feb. Report No.: NCT04639050. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04639050"},{"issue":"1","key":"541_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 2023; 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"541_CR34","unstructured":"Commissioner O of the. FDA Grants Accelerated Approval for Alzheimer\u2019s Drug [Internet]. FDA. FDA; 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug. Accessed 22 Nov 2022."},{"key":"541_CR35","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis Internet. 2022. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimers Dis Internet."},{"key":"541_CR36","unstructured":"Maloney and Pallone Release Staff Report on Review, Approval, and Pricing of Biogen\u2019s Alzheimer\u2019s Drug Aduhelm [Internet]. Democr. Energy Commer. Comm. 2022. https:\/\/democrats-energycommerce.house.gov\/newsroom\/press-releases\/maloney-and-pallone-release-staff-report-on-review-approval-and-pricing-of. Accessed 3 Mar 2023."},{"key":"541_CR37","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"issue":"6","key":"541_CR38","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cpt.2875","volume":"113","author":"I Gueorguieva","year":"2023","unstructured":"Gueorguieva I, et al. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's disease. Clin Pharmacol Ther. 2023; 113(6):1258\u201367. https:\/\/doi.org\/10.1002\/cpt.2875.","journal-title":"Clin Pharmacol Ther"},{"key":"541_CR39","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB DeMattos","year":"2012","unstructured":"DeMattos RB, et al. A plaque-specific antibody clears existing \u03b2-amyloid Plaques in Alzheimer\u2019s disease mice. Neuron. 2012;76:908\u201320.","journal-title":"Neuron"},{"key":"541_CR40","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"541_CR41","unstructured":"Lilly\u2019s Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer\u2019s Disease | Eli Lilly and Company [Internet]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-donanemab-significantly-slowed-cognitive-and-functional. Accessed 13 May 2023."},{"key":"541_CR42","unstructured":"Sims JR et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA [Internet]. 2023. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2807533. Accessed 25 July 2023."},{"key":"541_CR43","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","volume":"79","author":"E Teng","year":"2022","unstructured":"Teng E, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79:758.","journal-title":"JAMA Neurol"},{"key":"541_CR44","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","volume":"4","author":"IA Qureshi","year":"2018","unstructured":"Qureshi IA, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement Transl Res Clin Interv. 2018;4:746\u201355.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"541_CR45","doi-asserted-by":"publisher","unstructured":"Top-line results from tango, a phase 2 study of gosuranemab in participants with mild cognitive impairment due to alzheimer\u2019s disease and mild alzheimer\u2019s disease | Cochrane Library [Internet]. [cited 2022 Nov 29]. https:\/\/doi.org\/10.1002\/central\/CN-02348792\/full.","DOI":"10.1002\/central\/CN-02348792\/full"},{"key":"541_CR46","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acn3.176","volume":"2","author":"K Yanamandra","year":"2015","unstructured":"Yanamandra K, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2:278\u201388.","journal-title":"Ann Clin Transl Neurol"},{"key":"541_CR47","unstructured":"AbbVie. A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer\u2019s Disease [Internet]. clinicaltrials.gov; 2022 Aug. Report No.: NCT02880956. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02880956"},{"key":"541_CR48","unstructured":"AbbVie. An Extension Study of ABBV-8E12 in Early Alzheimer\u2019s Disease [Internet]. clinicaltrials.gov; 2022 Aug. Report No.: NCT03712787. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03712787"},{"key":"541_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","volume":"48","author":"GA Jicha","year":"1997","unstructured":"Jicha GA, et al. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128\u201332.","journal-title":"J Neurosci Res"},{"key":"541_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","volume":"5","author":"JS Andrews","year":"2019","unstructured":"Andrews JS, et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials. Alzheimers Dement Transl Res Clin Interv. 2019;5:354\u201363.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"541_CR51","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3233\/JAD-142643","volume":"47","author":"CB Malpas","year":"2015","unstructured":"Malpas CB, et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Tau and Amyloid-\u03b2 cerebrospinal fluid biomarkers have differential relationships with cognition in mild cognitive impairment. J Alzheimers Dis JAD. 2015;47:965\u201375.","journal-title":"J Alzheimers Dis JAD."},{"key":"541_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127396","volume":"10","author":"F Blanc","year":"2015","unstructured":"Blanc F, et al. Cortical thickness in dementia with lewy bodies and alzheimer\u2019s disease: a comparison of prodromal and dementia stages. PLoS ONE. 2015;10: e0127396.","journal-title":"PLoS ONE"},{"key":"541_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p628","volume":"380","author":"JH Tanne","year":"2023","unstructured":"Tanne JH. Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer\u2019s drug. BMJ. 2023;380: p628.","journal-title":"BMJ"},{"key":"541_CR54","unstructured":"Lecanemab-irmb (LEQEMBI) Criteria for Use February 2023."},{"key":"541_CR55","unstructured":"ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer\u2019s Disease [Internet]. ICER. https:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-final-evidence-report-and-policy-recommendations-on-aducanumab-for-alzheimers-disease\/. Accessed 3 Mar 2023."},{"key":"541_CR56","unstructured":"ICER Publishes Evidence Report on Lecanemab for Alzheimer\u2019s Disease [Internet]. ICER. https:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-evidence-report-on-lecanemab-for-alzheimers-disease\/. Accessed 19 Mar 2023."},{"key":"541_CR57","unstructured":"Commissioner O of the. FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval [Internet]. FDA. FDA; 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Accessed 9 Aug 2023."},{"key":"541_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","volume":"613","author":"S Reardon","year":"2023","unstructured":"Reardon S. FDA approves Alzheimer\u2019s drug lecanemab amid safety concerns. Nature. 2023;613:227\u20138.","journal-title":"Nature"},{"key":"541_CR59","unstructured":"Constantino AK. Eli Lilly expects FDA decision on Alzheimer\u2019s treatment donanemab by the end of the year [Internet]. CNBC. 2023. https:\/\/www.cnbc.com\/2023\/07\/17\/alzheimers-eli-lilly-expects-fda-decision-on-donanemab-by-year-end.html. Accessed 9 Aug 2023."},{"key":"541_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1474-4422(22)00529-4","volume":"22","author":"S Mead","year":"2023","unstructured":"Mead S, Fox NC. Lecanemab slows Alzheimer\u2019s disease: hope and challenges. Lancet Neurol. 2023;22:106\u20138.","journal-title":"Lancet Neurol"},{"key":"541_CR61","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamaneurol.2023.0123","volume":"80","author":"DA Wolk","year":"2023","unstructured":"Wolk DA, et al. A step forward in the fight against dementia\u2014are we there yet? JAMA Neurol. 2023;80:429\u201330.","journal-title":"JAMA Neurol"},{"key":"541_CR62","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/gps.3946","volume":"28","author":"S Todd","year":"2013","unstructured":"Todd S, et al. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28:1109\u201324.","journal-title":"Int J Geriatr Psychiatry"},{"key":"541_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13195-017-0272-8","volume":"9","author":"F Blanc","year":"2017","unstructured":"Blanc F, et al. Long-term cognitive outcome of Alzheimer\u2019s disease and dementia with Lewy bodies: dual disease is worse. Alzheimers Res Ther. 2017;9:47.","journal-title":"Alzheimers Res Ther"},{"key":"541_CR64","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza F, et al. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15:73\u201388.","journal-title":"Nat Rev Neurol"},{"key":"541_CR65","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41398-021-01532-2","volume":"11","author":"M Linard","year":"2021","unstructured":"Linard M, et al. Herpes simplex virus, early neuroimaging markers and incidence of Alzheimer\u2019s disease. Transl Psychiatry. 2021;11:414.","journal-title":"Transl Psychiatry"},{"key":"541_CR66","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, et al. Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553\u201362.","journal-title":"Neurology"},{"key":"541_CR67","unstructured":"TauRx Announces Results from Phase 3 Alzheimer\u2019s Disease Study,\u2026 [Internet]. TauRx Pharm. https:\/\/taurx.com\/news-insights\/taurx-announces-results-from-phase-3-alzheimers-disease-study-lucidity-assuring-path-for-regulatory-submissions. Accessed 27 Mar 2023."},{"key":"541_CR68","unstructured":"Novo Nordisk A\/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer\u00b4s Disease (EVOKE) [Internet]. clinicaltrials.gov; 2023 Mar. Report No.: NCT04777396. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04777396"},{"key":"541_CR69","unstructured":"Novo Nordisk A\/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer\u00b4s Disease (EVOKE Plus) [Internet]. clinicaltrials.gov; 2023 Mar. Report No.: NCT04777409. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04777409"},{"key":"541_CR70","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3233\/JAD-220045","volume":"87","author":"J Sarto","year":"2022","unstructured":"Sarto J, et al. Evolution of clinical-pathological correlations in early-onset alzheimer\u2019s disease over a 25-year period in an academic brain bank. J Alzheimers Dis JAD. 2022;87:1659\u201369.","journal-title":"J Alzheimers Dis JAD"},{"key":"541_CR71","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s40478-021-01260-0","volume":"9","author":"S Agrawal","year":"2021","unstructured":"Agrawal S, et al. The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer\u2019s dementia in older persons. Acta Neuropathol Commun. 2021;9:156.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"541_CR72","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/brain\/awad059","volume":"146","author":"JL Robinson","year":"2021","unstructured":"Robinson JL, et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain J Neurol. 2023;146(6):2557\u201369. https:\/\/doi.org\/10.1093\/brain\/awad059.","journal-title":"Brain J Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00541-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T06:14:15Z","timestamp":1699337655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00541-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00541-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arthur Esquer declares that he has no competing interests. Fr\u00e9d\u00e9ric Blanc was the national coordinator for France for the Eisai Delphia (E2027), Axovant Headway-DLB and Roche Graduate clinical trials; he had received honoraria from Roche, Eisai, and Biogen for oral presentations, and from Eisai for a participation in a board meeting. Nicolas Collongues has received honoraria for consulting or presentation from Alexion, Biogen Idec, Bristol-Myers Squibb, Horizon Therapeutics, Merck Serono, Novartis, Roche and Sanofi-Genzyme and is a member of the Editorial Board of the Journal de la Ligue Fran\u00e7aise contre la Scl\u00e9rose en plaques and the Neurology and Therapy Journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}